Study of outcome of naïve and previous nonresponder hepatitis C virus Egyptian children treated with combined therapy of pegylated interferon plus ribavirin

Egyptian Liver Journal

Volumn 4, Issue 3, 2014, Pages 87-93

  El Naghi, Suzan ^a   Mahmoud, Faten ^a  

^a National Hepatology and Tropical Medicine Research Institute NHTMRI   (Egypt)

Author keywords

HCV infected children; HCV non responders; HCV combined therapy

Indexed keywords

EID: 84904999690     PISSN: 20906218     EISSN: 20906226     Source Type: Journal    
DOI: 10.1097/01.ELX.0000451421.61577.04     Document Type: Article

References (24)

1. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32:111-115. (Pubitemid 30432374)
2. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33:248-253. (Pubitemid 32016908)
3. Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L, Nafeh M, et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66:633-638.
4. Nafeh MA, Medhat A, Shehata M, Nafeh MA, Medhat A, Shehata M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg 2000; 63:236-241. (Pubitemid 32537556)
5. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355:887-891. (Pubitemid 30137669)
6. Jara P, Resti M, Hierro L, Giacchino R, Cristiana B, Lucia Z, et al. Chronic HCV infection in childhood: clinical pattern and evolution in 224 white children. Clin Infect Dis 2003; 36:275-280. (Pubitemid 36169661)
7. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50:402-411.
8. Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009; 29 (Suppl 1):39-48.
9. Varghese R, Al-Khaldi J, Asker H, Fadili AA, Al Ali J, Hassan FA. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009; 56:218-222.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa2-b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
11. Fried MW, Shiffman MI, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa 2-b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
12. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18:99-104.
13. Pawlowska M, Pilarczyk M, Halota W. Virological response to treatment with pegylated interferon alfa-2 b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16:CR 616-CR 621.
14. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci G, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50. (Pubitemid 351171040)
15. Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions. Clin Infect Dis 2012; 55: 639-644.
16. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin non-responder patients. Gastroenterology 2006; 130:1098-1106.
17. Gerner P, Hilbich J, Wenzl TG, Behrens R, Walther F, Kliemann G, et al. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment. J Pediatr Gastroenterol Nutr 2010; 51:187-190.
18. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C infection: 2011 practice guidelines by the American Association for Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
19. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry chronic hepatitis C infection: developing direct-acting antiviral agents for treatment. Available at: http://www.fda.gov/downloads/ Drugs/Guidance Compliance Regulatory Information/Guidances/UCM225333.pdf. [Accessed 4 September 2010].
20. Douglas LN, Ke-qin Hu. Clinical evaluation of chronic hepatitis C and indication for HCV treatment. North Am J Med Sci 2014; 7:12-18.
21. Akhan SC, Gurel E, Sayan M. The sustained virological response of non responder hepatitis C patients with retreatment. Indian J Pathol Microbiol 2011; 54:81-84.
22. Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007; 52:732-736.
23. Jensen DM, Marcillin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Retreatment of patients with chronic hepatitis C who do not respond to pegylated interferon alpha 2b: a randomized trial. Ann Intern Med 2009; 150:528-540.
24. Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infected children (a pilot study). Indian J Pediatr 2009; 76:895-898.